Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The story makes clear the “big unknown” remains the price and “how much people are willing to spend to cut a day or so off of a bout of flu.” The story reports that Genentech, the drug’s manufacturer, said it’s too early to comment on the drug’s U.S. price. The story also notes that in Japan, where the drug was invented, it “sells for the equivalent of about $43.50.” The story uses terms like “a little more than a day” and “nearly a day” and “substantially” to describe the drug’s reduction in flu symptoms, fever, and coughing and sneezing, respectively. It does not explain, as the news release does, that: “Similar efficacy results were seen between baloxavir marboxil and [Tamiflu] in relation to duration of symptoms and fever reduction.” In other words, on the symptom front, both drugs were the same. According to the news release, a difference was seen in the length of time the virus was shed from the body (presumably through coughing and sneezing): 24 hours for baloxavir marboxil verses 72 hours for Tamiflu. The news release also states that there was also a difference seen in the level of virus in the nose and throat, but it provides no precise numbers. It is not known whether this benefit translates into less infection transmission, and the story should have made that clear. The news release issued by Genentech about the FDA’s decision to grant priority review describes baloxavir marboxil’s most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu. The STAT News story does not mention any potential harms. This evidence comes from the randomized phase III Capstone-1 study the FDA will review, which included 1,436 people in the US and Japan. It excluded people older than 64. The news story does not note this exclusion, nor does it state a key problem with this study: It has never been published in a peer-reviewed journal (instead, a study abstract was released as part of ID Week 2017). This means the full data analysis has never been seen by anyone other than the researchers. We explained why this is important in February 2018, when we discussed news coverage of the drug’s approval in Japan. The 2017-2018 flu season was the worst the US had experienced in nearly a decade. The flu impacted the entire country, and was responsible for 172 pediatric deaths. The news article did not use these or any other flu-related statistics to increase fear about the flu and, in turn, the need for this medication. The article includes two sources: Mark Eisner, Genentech’s VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization’s influenza collaborating center at St. Jude Children’s Research Hospital in Memphis. Eisner’s affiliation with Genentech, the drug’s manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on what–if anything–is known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths. The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and that baloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days. It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication. The story explains that it’s been more than 20 years since a new class of flu drug has been developed and marketed. (It is available in Japan.) The catalyst for the story was a news release issued by Genentech about the FDA granting priority review of baloxavir marboxil, but the story does not use direct quotes from the news release.
Example Output: A flu drug — shown to reduce the duration of symptoms — could upend treatment in U.S.

Example Input: File photo shows a young carer holding the hands of an elderly woman in a residential home for the elderly in Planegg near Munich June 19, 2007. REUTERS/Michaela Rehle The study, reported on Sunday in the journal BioMed Central BMC Neurology, involved 12 patients who had greatly improved language recall shortly after treatment with Enbrel, or etanercept, an anti-inflammatory drug co-marketed by Amgen and Wyeth. “We often see verbal effects within a few minutes of the first dose,” said Dr. Edward Tobinick, director of the Institute for Neurological Research, a private medical group inc., in Los Angeles, who led the study. Tobinick invented and holds several patents on a special method of injecting the drug into the neck. He said he charges anywhere between $10,000 and $40,000 per patient for the treatments. In January, Tobinick’s report on a single patient, and release of a striking video, drew the attention of the Alzheimer’s Association, which released a statement expressing concern. “People with Alzheimer’s and their families may place undue value on this new finding based on the dramatic language used in its description and the apparent immediate effect,” the group said. “We need to see work in other laboratories by scientists without financial interest in the product,” it added. Dr. Sam Gandy, chairman of the Alzheimer’s Association’s medical and science council, said the latest study, done at Tobinick’s clinic, does not offer that independent confirmation. “It’s still not a proper trial,” Gandy said. Tobinick believes the drug may work in the brain by blocking an excess of tumor necrosis factor-alpha or TNF-alpha, which may affect communication in the brain. The study looked at language difficulties, such as in finding words, in 12 patients with mild-to-severe Alzheimer’s disease who were administered etanercept weekly for six months. “There was a significant improvement in the majority of the verbal measures that were studied. The remainder showed a tendency toward improvement, which was not significant,” Tobinick said in a telephone interview. He said the study provides evidence that “excess TNF, in the Alzheimer brain, may offer a new way to address this language dysfunction.”   Tobinick acknowledged the study is limited because people knew they were getting the drug. Alzheimer’s patients in such open-label studies often show improvement. “Placebo effect is an enormous problem in open-label studies,” said Dr. Scott Turner, incoming director of the Memory Disorders Program at Georgetown University Medical Center in Washington. Turner said the true test must come from a more scientifically rigorous double-blind, placebo-controlled, randomized clinical trial. In such studies, patients receive either a dummy treatment or an active agent, and neither the doctor nor the patient knows which. Amgen has also expressed concern about the research, claiming there has been insufficient evidence so far. “This off-label, unapproved treatment, administered by Dr. Edward Tobinick, is not supported nor endorsed by Amgen,” the company said in April on its Web site. A video showing one woman's response to the drug in a sister study can be found at : here
Example Output: Drug restores speech in Alzheimer's; experts worry.

Example Input: The workers that included radiology technicians, respiratory therapists and pharmacy workers picketed the medical centers in Los Angeles, San Francisco, San Diego, Irvine and Davis. They rang bells, wore green-shirts and carried signed that said “End Outsourcing.” Another 24,000 other California union workers, ranging from truck drivers to gardeners and cooks, were striking in sympathy, said John de los Angeles, spokesman for the American Federation of State, County and Municipal Employees Local 3299. Emergency rooms remained open at the hospitals but officials said the strike would still affect thousands of patients. The UC San Francisco hospital rescheduled more than 4,000 appointments at its medical center and two associated clinics and rescheduled 241 surgeries, including “pretty high-risk” gynecological and colorectal operations, said chief operating officer Sheila Antrum. Ten patients, including children, were sent to other hospitals, she said. The hospital had 500 temporary employee replacements on hand, including respiratory therapists, social workers, pharmacists and housekeepers, she said. “My focus here is that we get through everything with the usual great care we have,” she said. The union said some of its workers would keep working despite the strike to ensure patient safety, and it also has a “patient protection task force,” a group of emergency services staffers who are prepared to cross the picket lines if they are needed to work because of a medical crisis, de los Angeles said. Patient care workers have been without a contract since December. Talks and mediation efforts have stalled, and the university plans to impose new employment terms next month, de los Angeles said. The union wants the university to stop outsourcing low-wage work that it claims is fueling widening income, racial and gender gaps for workers at UC’s hospitals, clinics campuses and research facilities. The same issue prompted a three-day walkout by 53,000 UC workers last May, including custodians and cafeteria workers. Nurses and other medical workers walked out then in sympathy. “They’re destroying what were once career pathways to the middle-class for our state’s diverse population and are damaging the quality of service that we provide to students, patients, and everyday Californians,” Monica De Leon, vice president of AFSCME Local 3299′s Patient Care Technical Unit, said in a statement. A University of California statement said union leaders spread false information about outside service contracts and that the number of unionized patient care workers increased nearly 19 percent over the past five years while outsourcing contracts had stayed relatively flat. The employment deal to be implemented next month would grant 3-percent-a-year raises for the next 4 years for patient care and service staff, as well as offering a health plan at the same rates as other UC employees with similar salaries. The union, however, is demanding an “unrealistic and unreasonable” 8 percent annual wage increase that is nearly triple what other UC employees have received, UC Office of the President spokeswoman Claire Doan said in a statement. The statement accused union leaders of “throwing a tantrum ... putting their agenda above the needs of patients, students and the public.” But de los Angeles, the union spokesman, said the new employment terms do nothing to deal with the threat of replacing union jobs with cheaper outside contractors who are ill-paid and lack benefits. “What good is a raise if our job is allowed to be outsourced tomorrow?” he said.
Example Output:
About 15,000 strike at University of California hospitals.